LinkedIn Icon Twitter Icon
March 19-21, 2019 | Boston, MA

Advancing ICI-containing IO-combination therapies is central to getting the full therapeutic benefit out of ICIs. Selecting the right combination partners and strategies are essential to the making the correct decision.

This industry-led meeting will focus on how the response rate to checkpoint combinations can be enhanced to impact every stage of the cancer immunity cycle, as well as shed light on the specific challenges that come with combining IO therapies with ICIs.

Through interactive workshops, panel discussions and roundtables, this is a great opportunity to gain practical implementable insight into IO combo development strategy.

View the full event guide for more information.

"Great meeting, very informative, great to see what other companies are working on in the field of cancer immunotherapy."

Genentech

"This conference was of outstanding value. First class presentations, great opportunity for networking and perfect logistics."

AstraZeneca